{"entity":{"id":"nct07510802","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC","aka":[],"tldr":"A phase 1/2 trial of Dual-target CAR-NK cells in HER2-positive breast cancer and triple-negative breast cancer, run by Beijing Biotech, now recruiting.","summary":"Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC is a phase 1/2 interventional study registered as NCT07510802 by Beijing Biotech, with 60 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: Dual-target CAR-NK cells and Lymphodepleting.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07510802","url":"https://clinicaltrials.gov/study/NCT07510802"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive","tnbc","tnbc-metastatic"],"sections":[],"technologies":[],"targets":["her2","ror1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07510802","phase":"1/2","setting":"Phase 1/2, Biomarker-guided, Open-label Study of Allogeneic Dual-target CAR-NK Cells Directed Against HER2/ERBB2, MUC1, and/or ROR1 in Patients With Advanced or Metastatic Breast Cancer (Including HER2-positive and Triple-negative Disease).","sponsor":"Beijing Biotech","started":"2026-02-02","startedType":"actual","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07510802/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"ror1","kind":"target","name":"ROR1","route":"/targets/ror1/"}]}}